Abstract
This meta-analysis reviewed interleukin 6 (IL-6) levels across various tumour stages, compared transdermal and oral estradiol levels on IL-6 and C-reactive protein (CRP), and examined the IL-6 and tumour necrosis factor alpha (TNF-a) levels in healthy versus breast cancer patients. This analysis covers studies from 2003 to 2020.
Results: IL-6 can be used as a prognostic biomarker for breast cancer, as levels are seen to increase as the cancer stage advances. While transdermal estradiol does not have any significant effects on IL-6 or CRP, oral estradiol seemed to display an increase in. The baseline IL-6 levels differ between control subjects and breast cancer patients, but there is minimal change in TNF-a levels. This meta-analysis study provided useful insight into the associations of IL-6 and breast cancer prognosis. It suggests that there is room for more research to be done to investigate the efficacy of oral versus transdermal estradiol, and the potential of elevated levels of IL-6 as diagnostic tools for the understanding of breast cancer prognosis.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Crowley, Keelin M.
(2025)
"A Meta-Analysis of the Relationship Between Estradiol, C-reactive Protein, Interleukin-6 and Tumour Necrosis Factor-alpha, and their Association with Breast Cancer Prognosis,"
International Undergraduate Journal of Health Sciences: Vol. 5:
Iss.
1, Article 4.
DOI: https://doi.org/10.61862/2811-5937.1088
Available at:
https://sword.mtu.ie/iujhs/vol5/iss1/4
Publisher
Munster Technological University
